Shattuck Labs, Inc. Increase (Decrease) in Deferred Revenue
Shattuck Labs, Inc. (STTK) reported Increase (Decrease) in Deferred Revenue of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2025-05-01
- Shattuck Labs, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was $5.38M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 9 month |
|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |
| 2024-03-31 | $5.38M 10-Q · filed 2025-05-01 | |
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |